Abstract
According to the current paradigm, the main cause of AD is the accumulation of neurotoxic amyloid beta (Aβ) peptide aggregates resulting from the cleavage of the amyloid precursor protein into peptides of different length, with the 42 amino acid long Aβ42 being the most toxic form. Aβ can aggregate and form plaques in the brain. It further promotes the hyperphosphorylation of the tau protein which forms characteristic neurofibrillary tangles and thereby loses its important role in axonal transport and contributes to neurodegeneration. Therefore, treatments have targeted Aβ, but clinical trials of immunotherapies caused severe side effects and showed that Aβ clearance alone did not result in any cognitive improvement. This leads to the question: what else promotes AD pathology? Here, we review data on systemic inflammation and the possible roles that the immune system might play in AD. Microglia and astrocytes are activated and secrete inflammatory cytokines and chemokines. Via a disturbed blood-brain barrier, peripheral immune cells are activated and recruited towards inflamed brain lesions and amyloid plaques, but due to the chronic nature of the amyloid burden and their reduced function, these cells are not able to control inflammation and the associated detrimental immune responses. In addition, age-related inflammation and chronic infection with herpes viruses might contribute to the systemic inflammation and exacerbate attempts to restore the balance of inflammation.
Keywords: Alzheimer Disease, CMV, HSV, immunity, Inflammation, leukocytes, T-cell differentiation.
Current Alzheimer Research
Title:Peripheral Immune Signatures in Alzheimer Disease
Volume: 13 Issue: 7
Author(s): David Goldeck, Jacek M. Witkowski, Tamas Fülop and Graham Pawelec
Affiliation:
Keywords: Alzheimer Disease, CMV, HSV, immunity, Inflammation, leukocytes, T-cell differentiation.
Abstract: According to the current paradigm, the main cause of AD is the accumulation of neurotoxic amyloid beta (Aβ) peptide aggregates resulting from the cleavage of the amyloid precursor protein into peptides of different length, with the 42 amino acid long Aβ42 being the most toxic form. Aβ can aggregate and form plaques in the brain. It further promotes the hyperphosphorylation of the tau protein which forms characteristic neurofibrillary tangles and thereby loses its important role in axonal transport and contributes to neurodegeneration. Therefore, treatments have targeted Aβ, but clinical trials of immunotherapies caused severe side effects and showed that Aβ clearance alone did not result in any cognitive improvement. This leads to the question: what else promotes AD pathology? Here, we review data on systemic inflammation and the possible roles that the immune system might play in AD. Microglia and astrocytes are activated and secrete inflammatory cytokines and chemokines. Via a disturbed blood-brain barrier, peripheral immune cells are activated and recruited towards inflamed brain lesions and amyloid plaques, but due to the chronic nature of the amyloid burden and their reduced function, these cells are not able to control inflammation and the associated detrimental immune responses. In addition, age-related inflammation and chronic infection with herpes viruses might contribute to the systemic inflammation and exacerbate attempts to restore the balance of inflammation.
Export Options
About this article
Cite this article as:
Goldeck David, M. Witkowski Jacek, Fülop Tamas and Pawelec Graham, Peripheral Immune Signatures in Alzheimer Disease, Current Alzheimer Research 2016; 13 (7) . https://dx.doi.org/10.2174/1567205013666160222112444
DOI https://dx.doi.org/10.2174/1567205013666160222112444 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Linezolid - The First Oxazolidinone in the Treatment of Nosocomial MRSA Pneumonia
Recent Patents on Anti-Infective Drug Discovery Insights from Exercise-induced Cardioprotection-from Clinical Application to Basic Research
Current Pharmaceutical Design Antithrombotic Treatment in the Prevention of Ischemic Stroke
Current Drug Targets Cellular Cardiomyoplasty – Challenges of a New Era
Current Tissue Engineering (Discontinued) Overview and Developments Regarding Functional Foods and Beverages
Current Nutrition & Food Science Antihistamines: Past Answers and Present Questions
Current Drug Safety Atherosclerosis is an Inflammatory Disorder After All
Current Topics in Medicinal Chemistry PCSK9 and LDLR The Yin-Yang in the Cellular Uptake of Cholesterol
Current Hypertension Reviews Bortezomib – First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews The Efficacy of Psychological Therapies for Specific Phobias in Adults and Some Unanswered Questions
Current Psychiatry Reviews Glucagon Like Peptide-1 and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Immunosuppression in Sepsis
Current Pharmaceutical Design Management of the Metabolic Syndrome as a Strategy for Preventing the Macrovascular Complications of Type 2 Diabetes: Controversial Issues
Current Diabetes Reviews Lipoic Acid as a Potential Therapy for Chronic Diseases Associated with Oxidative Stress
Current Medicinal Chemistry Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry
Current Neuropharmacology Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome
Current Pharmaceutical Design Nitric Oxide and Dietary Factors: Part IV Traditional Japanese Food (Soy Products, Fish and Tea)
Vascular Disease Prevention (Discontinued) Graphical Abstracts
Letters in Drug Design & Discovery